English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

To the Editor:Favilla and colleagues1 address the use of sulfonylureas in diabetic patients with stroke. The article deals with 2 important interrelated questions: first, a “safety question”—does prior use of sulfonylureas worsen stroke presentation or outcome? Second, an “efficacy question”—does prior use plus continued use of sulfonylureas during hospitalization for stroke favorably influence outcome? Given extensive preclinical evidence for the beneficial role of sulfonylureas in rodent models of stroke, and 2 prior retrospective analyses suggesting beneficial effects in patients with stroke when sulfonylureas are continued during hospitalization, it is important to assess the negative results from Favilla et al as it relates to the “efficacy question.” Important methodological considerations raise serious concerns about their conclusions.The “efficacy question” was studied previously by comparing diabetics who were on and continued on a sulfonylurea during hospitalization with diabetics not on a sulfonylurea. …

Letter by Simard et al Regarding Article, “Sulfonylurea Use Before Stroke Does Not Influence Outcome”